trending Market Intelligence /marketintelligence/en/news-insights/trending/3VoEqvJwrorUGg-QZY3O5Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Summa Equity buys majority stake in Olink Proteomics

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Gauging Supply Chain Risk In Volatile Times

Summa Equity buys majority stake in Olink Proteomics

Summa Equity purchased Sweden-headquartered life sciences company Olink Proteomics AB, which has developed technology for human biomarker discovery.

Under the deal, the private equity firm will become the company's majority shareholder, while its founder Ulf Landegren and the management team will continue as stockholders.

Moelis & Co. LLC served as financial adviser to Summa, White & Case was its legal adviser, LEK Consulting was its commercial adviser and KPMG was its accounting adviser. J.P. Morgan Securities LLC acted as financial adviser to Olink, while Wiggin, Dana LLP and Lindahl were its legal advisers.